Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)

Blum Kenneth^{1

2

3

4

5

6

7

8

9

10}, Modestino J Edward^{7

11}, Gondre Lewis C Marjorie^{7

12}, Baron David^{1

7}, Steinberg Bruce^{7

11}, Thanos K Panayotis^{7

13}, Downs B William¹⁰, Siwicki Davis^{6

7}, Lott Lisa⁷, Braverman R Eric⁴, Moran Mark⁷, Miller David⁸, Fried Lyle⁷, Badgaiyan D Rajendra^{7

14}

Affiliations

¹ Western University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA.
² Eotvos Loránd University, Institute of Psychology, Budapest, Hungary.
³ Department of Psychiatry, Wright State University Boonshoft School of Medicine and Dayton VA Medical Center, Dayton, OH, USA.
⁴ Department of Clinical Neurology, Path Foundation NY, New York, USA.
⁵ Department of Psychiatry, University of Vermont, Burlington, VM, USA.
⁶ Dominion Diagnostics, LLC., North Kingston, RI, USA.
⁷ Division of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
⁸ Division of Addiction Therapy Research, Nupathways, Inc., Meadow Ridge Dr. Innsbrook, MO, USA.
⁹ Division of Neurogenetic Research & Addiction Therapy, The Florida House Experience, Deerfield Beach, FL, USA.
¹⁰ Division of Nutrigenomics, Victory Nutrition International. LLC., Lederach, PA.
¹¹ Department of Psychology, Curry College, Milton, MA, USA.
¹² Departments of Anatomy & Psychiatry & Behavioral Sciences, Howard University School of Medicine, Washington, DC, USA.
¹³ Behavioral Neuropharmacology & Neuroimaging Laboratory on Addiction, Research Institute on Addictions, University of Buffalo, Buffalo, NY, USA.
¹⁴ Department of Psychiatry, Ichan School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 30957097
PMCID: PMC6448775

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)

Blum Kenneth et al. CPQ Neurol Psychol. 2018.

. 2018;1(2):https://www.cientperiodique.com/journal/fulltext/CPQNP/1/2/13.

Epub 2018 Dec 4.

Authors

Affiliations

¹ Western University Health Sciences, Graduate School of Biomedical Sciences, Pomona, CA.
² Eotvos Loránd University, Institute of Psychology, Budapest, Hungary.
³ Department of Psychiatry, Wright State University Boonshoft School of Medicine and Dayton VA Medical Center, Dayton, OH, USA.
⁴ Department of Clinical Neurology, Path Foundation NY, New York, USA.
⁵ Department of Psychiatry, University of Vermont, Burlington, VM, USA.
⁶ Dominion Diagnostics, LLC., North Kingston, RI, USA.
⁷ Division of Precision Addiction Management, Geneus Health, LLC., San Antonio, TX, USA.
⁸ Division of Addiction Therapy Research, Nupathways, Inc., Meadow Ridge Dr. Innsbrook, MO, USA.
⁹ Division of Neurogenetic Research & Addiction Therapy, The Florida House Experience, Deerfield Beach, FL, USA.
¹⁰ Division of Nutrigenomics, Victory Nutrition International. LLC., Lederach, PA.
¹¹ Department of Psychology, Curry College, Milton, MA, USA.
¹² Departments of Anatomy & Psychiatry & Behavioral Sciences, Howard University School of Medicine, Washington, DC, USA.
¹³ Behavioral Neuropharmacology & Neuroimaging Laboratory on Addiction, Research Institute on Addictions, University of Buffalo, Buffalo, NY, USA.
¹⁴ Department of Psychiatry, Ichan School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 30957097
PMCID: PMC6448775

Abstract

Background: We are facing a significant challenge in combatting the current opioid and drug epidemic worldwide. In the USA, although there has been notable progress, in 2017 alone 72,000 people died from a narcotic overdose. The NIAAA & NIDA continue to struggle with innovation to curb or eliminate this unwanted epidemic. The current FDA list of approved Medication Assistance Treatments (MATS) work by primarily blocking dopamine function and release at the pre-neuron in the nucleus accumbens. We oppose this option in the long term tertiary treatment but agree for short term harm reduction potential.

Bibliography presentation: As an alternative motif, the utilization of a well-researched neuro-nutrient called KB220 has been intensely investigated in at least 38 studies showing evident effects related to everything from AMA rate, attenuation of craving behavior, reward system activation including BOLD dopamine signaling, relapse prevention, as well as reduction in stress, anger, and aggressive behaviors. We are continuing research especially as it relates to genetic risk, including the now patented Genetic Addiction Risk Score (GARS^®) and the development of "Precision Addiction Management (PAM)" to potentially combat the opioid/psychostimulant epidemic.

Conclusion: Based on animal research and clinical trials as presented herein, the Pro-Dopamine Regulator known as KB220 shows promise in the addiction and pain space. Other neurobiological and genetic studies are required to help understand the mechanism of action of this neuro-nutrient. However, the evidence to date points to induction of "dopamine homeostasis"enabling an asymptotic approach for epigenetic induced "normalization" of brain neurotransmitter signaling and associated improved function in the face of either genetic or epigenetic impairment of the Brain Reward Cascade (BRC).With that said, we are encouraged about these results as published over the last 50 years and look forward to continued advancements related to appropriate nutrigenomic solutions to the millions of victims of all addictions (from drugs to food to smoking to gambling and gaming especially in our next generation) called Reward Surfeit Syndrome (RSS) in adolescents and Reward Deficiency Syndrome (RDS) in adulthood.

Keywords: Annotated; Genetic Addiction Risk Score (GARS®); Kb220; Precision Addiction Management (PAM®); Restoregen Variant.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interests Kenneth Blum and David Siwicki own a percentage of Geneus Health, and Igene holding genetic patents. KB owns 100% of Synaptamine, holding patents on KB220PAM. Drs. EJM, MCGL, PKT, DB, DS, and RDB are members of Geneus Health Scientific Advisory Board. Through Synaptamine a license has been granted to Victory Nutrition International whereby B. William Downs is the CEO. Synaptamine also licensed Nupathways whereby David Miller is an owner. There are no other conflicts of interest to declare.

Figures

See this image and copyright information in PMC

References

1. Blum K, Briggs AH, Trachtenberg MC, Delallo L & Wallace JE (1987). Enkephalinase inhibition: Regulation of ethanol intake in mice. Alcohol, 4(6), 449–456. - PubMed
1. Blum K, Wallace JE, Calhoun W, Tabor RG & Eubanks JD (1974). Ethanol narcosis in mice: serotonergic involvement. Experientia, 30(9), 1053–1054. - PubMed
1. Blum K, Calhoun W, Merritt J & Wallace JE. (1973). L-DOPA: effect on ethanol narcosis and brain biogenic amines in mice. Nature, 242(5397), 407–409. - PubMed
1. Blum K, Trachtenberg MC & Ramsay JC (1988). Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. Int J Addict, 23(9), 991–998. - PubMed
1. Blum K, Trachtenberg MC, Elliott CE, Dingler ML, Sexton RL, et al. (1988). Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. Alcohol, 5(6), 481–493. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)

Affiliations

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous